Research papers: Skin CancerChemopreventive effects of various concentrations of α-santalol on skin cancer development in CD-1 miceDwivedi, C; Maydew, E R; Hora, J J; Ramaeker, D M; Guan, XiangmingAuthor Information Department of Pharmaceutical Sciences, College of Pharmacy, Box 2202 C, South Dakota State University, Brookings, SD 57007, USA Correspondence to: Chandradhar Dwivedi. Fax: (605) 688 5993 E-mail: Chandradhar.Dwivedi@sdstate.edu Received 18 October 2004 Accepted 28 December 2004 European Journal of Cancer Prevention: October 2005 - Volume 14 - Issue 5 - p 473-476 doi: 10.1097/01.cej.0000178075.20124.2a Buy Metrics Abstract Previous studies from this laboratory have indicated that α-santalol (5%) provides chemopreventive effects in 7,12-dimethylbenz[a]anthracene (DMBA)-initiated and 12-O-tetradecanoylphorbol-13-acetate (TPA)-promoted skin cancer in CD-1 and SENCAR mice. Skin cancer development is associated with increased ornithine decarboxylase (ODC) activity, DNA synthesis and rapid proliferation of epidermal cells. The purpose of this investigation was to determine the effects of various concentrations (1.25% and 2.5%) of α-santalol on DMBA-initiated and TPA-promoted skin cancer development, TPA-induced ODC activity, and DNA synthesis in CD-1 mice. α-Santalol treatment at both concentrations (1.25% and 2.5%) prevented the skin cancer development. α-Santalol treatment (1.25% and 2.5%) resulted in a significant decrease in the TPA-induced ODC activity and incorporation of [3H]thymidine in DNA in the epidermis of CD-1 mice. There was no significant difference in the effects of 1.25% and 2.5% α-santalol on tumour incidence, multiplicity, epidermal TPA-induced ODC activity, or DNA synthesis in CD-1 mice. © 2005 Lippincott Williams & Wilkins, Inc.